Schizophrenia guidelines across the world: A selective review and comparison

International Review of Psychiatry

Volumn 23, Issue 4, 2011, Pages 379-387

  Gaebel, Wolfgang ^a   Riesbeck, Mathias ^a   Wobrock, Thomas ^b,c  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c Darmstadt Dieburg Clinics   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

APA GUIDELINE; CLINICAL DECISION MAKING; CLINICAL EVALUATION; CLINICAL PRACTICE; DRUG SENSITIVITY; EVIDENCE BASED MEDICINE; GERMAN PSYCHIATRIC ASSOCIATION GUIDELINE; HEALTH CARE QUALITY; HUMAN; NICE GUIDELINE; PATIENT COMPLIANCE; PORT GUIDELINE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; RANZCP GUIDELINE; REVIEW; SCHIZOPHRENIA; SCORING SYSTEM; TREATMENT RESPONSE;

EVIDENCE-BASED MEDICINE; HEALTHCARE DISPARITIES; HUMANS; MENTAL HEALTH SERVICES; PRACTICE GUIDELINES AS TOPIC; SCHIZOPHRENIA;

EID: 80054934207     PISSN: 09540261     EISSN: 13691627     Source Type: Journal    
DOI: 10.3109/09540261.2011.606801     Document Type: Review

References (40)

1. AGREE (2009). The AGREE II instrument. Available at www.agreetrust.org
2. AGREE Collaboration (2001). Appraisal of Guidelines for Research and Evaluation (AGREE) instrument. Available at www.agreecollaboration.org.
3. AGREE Collaboration (2003a). Appraisal of Guidelines for Research and Evaluation (AGREE) instrument and training material. Available at www.agreecollaboration.org.
4. AGREE Collaboration (2003b). Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: The AGREE project. Quality and Safety in Health Care, 12, 18-23.
5. American Psychiatric Association (APA) (2004). Practice guideline for the treatment of patients with schizophrenia, second edition. American Journal of Psychiatry, 161, S1-56.
6. Birchwood, M., Todd, P. & Jackson, C. (1998). Early intervention in psychosis. The critical period hypothesis. British Journal of Psychiatry, 172, S53-59.
7. Brouwers, M.C., Kho, M.E., Browman, G.P., Burgers, J.S., Cluzeau, F., Feder, G., ...AGREE Next Steps Consortium (2010). AGREE II: Advancing guideline development, reporting and evaluation in health care. Canadian Medical Association Journal, 182, E839-842.
8. Fervers, B., Burgers, J.S., Voellinger, R., Brouwers, M., Browman, G.P., Graham, I.D., ...The ADAPTE Collaboration (2011). Guideline adaptation: An approach to enhance efficiency in guideline development and improve utilisation. Quality and Safety in Health Care, 20, 228-236.
9. Field, M.J. & Lohr, K.N. (1992). Guidelines for Clinical Practice: From Development to Use. Washington, DC: Institute of Medicine, National Academy Press. P. 2.
10. Gaebel, W., Falkai, P., Weinmann, S. & Wobrock, T. (2005a). Behandlungsleitlinie Schizophrenie [Schizophrenia treatment guideline]. In: Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN) (Eds). S3 Praxisleitlinien in Psychiatrie und Psychotherapie. [S-3- Practice Guidelines in Psychiatry and Psychotherapy] Darmstadt: Steinkopf Verlag,
11. Gaebel, W., Weinmann, S., Sartorius, N., Rutz, W. & McIntyre, J.S. (2005b). Schizophrenia practice guidelines: International survey and comparison. British Journal of Psychiatry, 187, P. 248.
12. Gaebel, W., Riesbeck, M., Wölwer, W., Klimke, A., Eickhoff, M., von Wilmsdorff, M., ...Möller, H.J. (2007). Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia. One-year results of a randomized controlled trial within the German Research Network on Schizophrenia. Journal of Clinical Psychiatry, 68, 1763-1774. (Pubitemid 350247506)
13. Gaebel, W., Riesbeck, M., Wölwer, W., Klimke, A., Eickhoff, M., von Wilmsdorff, M., ...German Study Group on First-Episode Schizophrenia (2011). Relapse prevention in first-episode schizophrenia-maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia. Journal of Clinical Psychiatry, 72, 205-218.
14. Gaebel, W., Schreiner, A., Bergmans, P., de Arce, R., Rouillon, F., Cordes, J., ...Smeraldi, E. (2010). Relapse prevention in schizophrenia and schizoaffective disorder with risperidone longacting injectable vs quetiapine: Results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology, 35, 2367-2377.
15. Grimshaw, J.M., Thomas, R.E., MacLennan, G., Fraser, C., Ramsay, C.R., Vale, L., ...Donaldson, C. (2004). Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technology Assessment, 8, iii-iv, 1-72.
16. Jobe, T.H. & Harrow, M. (2005). Long-term outcome of patients with schizophrenia: A review. Canadian Journal of Psychiatry,50, 892-900. (Pubitemid 43161743)
17. Jones P.B., Barnes T.R., Davies L., Dunn G., Lloyd H., Hayhurst K.P., Murray R.M., Markwick A., Lewis S.W. (2006). Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry, 63(10), 1079-87. (Pubitemid 44498387)
18. Kahn, R.S., Fleischhacker, W.W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I.P., ...EUFEST study group (2008). Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: An open randomised clinical trial. Lancet, 371, 1085-1097. (Pubitemid 351418005)
19. Kreyenbuhl, J., Buchanan, R.W., Dickerson, F.B. & Dixon, L.B.; Schizophrenia Patient Outcomes Research Team (PORT) (2010). The Schizophrenia Patient Outcomes Research Team (PORT): Updated treatment recommendations 2009. Schizophrenia Bulletin, 36, 94-103.
20. Lehman, A.F. & Steinwachs, D.M. (1998). Translating research into practice: The Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophrenia Bulletin, 24, 1-10. (Pubitemid 28128486)
21. Leucht, S., Corves, C., Arbter, D., Engel, R.R., Li, C. & Davis, J.M. (2009a). Second-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis. Lancet, 373, 31-41.
22. Leucht, S., Kissling, W. & Davis, J.M. (2009b). Second-generation antipsychotics for schizophrenia: Can we resolve the conflict? Psychological Medicine, 39, 1591-1602.
23. Lieberman, J.A., Stroup, T.S., McEvoy, J.P., Swartz, M.S., Rosenheck, R.A., Perkins, D.O., Keefe, R.S., Davis, S.M., Davis, C.E., Lebowitz, B.D., Severe, J., Hsiao, J.K. (2005). Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med, 353, 1209-23.
24. Lugtenberg, M., Burgers, J.S. & Westert, G.P. (2009). Effects of evidence-based clinical practice guidelines on quality of care: A systematic review. Quality and Safety in Health Care, 18, 385-392.
25. McGorry, P., Killackey, E., Elkins, K., McGorry, P., Killackey, E., Elkins, K....RANZCP Clinical Practice Guideline Team for the Treatment of Schizophrenia (2003). Summary Australian and New Zealand clinical practice guideline for the treatment of schizophrenia. Australasian Psychiatry, 11, 136-147. (Pubitemid 36805724)
26. Menezes, N.M., Arenovich, T. & Zipursky, R.B. (2006). A systematic review of longitudinal outcome studies of first-episode psychosis. Psychological Medicine, 36, 1349-1362. (Pubitemid 44355971)
27. Möller, H.J., Riedel, M., Jäger, M., Wickelmaier, F., Maier, W., Kühn, K.U., ...Gaebel, W. (2008). Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. International Journal of Neuropsychopharmacology, 11, 985-997.
28. Murray, C.J.L. & Lopez, A.D. (1996). The Global Burden of Disease: a Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020. Cambridge, Harvard School of Public Health on behalf of the World Health Organization and the World Bank.
29. NICE (2002). Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care. NICE Clinical Guideline 1. London: National Institute for Health and Clinical Excellence. Available at www.nice.org.uk.
30. NICE (2007). The Guidelines Manual. London: National Institute for Health and Clinical Excellence. NICE Clinical guideline Available at www.nice.org.uk
31. NICE (2009). Schizophrenia. Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care. NICE Clinical Guideline 82. London: National Institute for Health and Clinical Excellence. Available at http//guidance.nice.org.uk/CG82.
32. Ollenschläger, G., Marshall, C., Qureshi, S., Rosenbrand, K., Burgers, J., Mäkelä, M., ...Board of Trustees 2002, Guidelines International Network (G-I-N) (2004). Improving the quality of health care: Using international collaboration to inform guideline programmes by founding the Guidelines International Network (G-I-N). Quality and Safety in Health Care, 13, 455-460.
33. Rosenheck, R.A., Krystal, J.H., Lew, R., Barnett, P.G., Fiore, L., Valley, D.,CSP555 Research Group (2011). Long-acting risperidone and oral antipsychotics in unstable schizophrenia. New England Journal of Medicine, 364, 842-851.
34. Royal Australian and New Zealand College of Psychiatrists (RANZCP) (2005). Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Australian and New Zealand Journal of Psychiatry, 39, 1-30.
35. Tandon, R., Nasrallah, H.A. & Keshavan, M.S. (2010). Schizophrenia, 'Just the facts' 5. Treatment and prevention. Past, present, and future. Schizophrenia Research, 122, 1-23.
36. Watt, D.C., Katz, K. & Shepherd, M. (1983). The natural history of schizophrenia: A 5-year prospective follow-up of a representative sample of schizophrenics by means of standardized clinical and social assessment. Psychological Medicine, 13, 663-670. (Pubitemid 13019030)
37. Weinmann, S., Koesters, M. & Becker, T. (2007). Effects of implementation of psychiatric guidelines on provider performance and patient outcome: Systematic review. Acta Psychiatria Scandinavica, 115, 420-433. (Pubitemid 46733691)
38. WHO (2008). The global burden of disease: 2004 update. Geneva: World Health Organization.
39. Wobrock, T., Weinmann, S., Falkai, P. & Gaebel, W. (2009). Quality assurance in psychiatry: Quality indicators and guideline implementation. European Archives of Psychiatry and Clinical Neuroscience, 259, S219-226.
40. Wölwer, W., Buchkremer, G., Häfner, H., Klosterkötter, J., Maier, W., Möller, H.J. & Gaebel, W. (2003). German Research Network on Schizophrenia-Bridging the gap between re search and care. European Archives of Psychiatry and Clinical Neuroscience, 253, 321-329.